Leerink Partnrs Decreases Earnings Estimates for Pharvaris

Pharvaris (NASDAQ:PHVS) – Leerink Partnrs decreased their FY2026 EPS estimates for shares of Pharvaris in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now expects that the company will post earnings per share of ($2.87) for the year, down from their previous estimate of ($2.34). The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris Price Performance

Shares of Pharvaris stock opened at $19.32 on Wednesday. Pharvaris has a fifty-two week low of $15.21 and a fifty-two week high of $33.00. The firm has a market capitalization of $1.01 billion, a P/E ratio of -6.90 and a beta of -3.06. The company’s 50 day moving average price is $19.37 and its two-hundred day moving average price is $19.35.

Institutional Trading of Pharvaris

A number of hedge funds have recently added to or reduced their stakes in PHVS. Novo Holdings A S boosted its position in Pharvaris by 47.7% in the second quarter. Novo Holdings A S now owns 1,725,000 shares of the company’s stock valued at $32,430,000 after buying an additional 556,970 shares in the last quarter. Deerfield Management Company L.P. Series C boosted its position in Pharvaris by 31.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 1,397,279 shares of the company’s stock valued at $26,269,000 after buying an additional 335,687 shares in the last quarter. Patient Square Capital LP acquired a new stake in Pharvaris in the third quarter valued at approximately $4,488,000. State Street Corp acquired a new stake in Pharvaris in the third quarter valued at approximately $1,000,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pharvaris in the third quarter valued at approximately $906,000.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.